📊 MMSI Key Takeaways
Is Merit Medical Systems Inc. (MMSI) a Good Investment?
Merit Medical Systems demonstrates robust fundamental health with strong revenue growth (11.8% YoY), solid profitability expansion (8.5% net margin), and exceptional cash generation (215.7M FCF). The company maintains fortress-like balance sheet metrics with 4.34x current ratio, 0.46x debt/equity, and 23.0x interest coverage, positioning it well for sustainable operations and strategic investments.
Merit Medical is delivering double-digit revenue growth with strong gross margins and solid operating profitability, translating into healthy free cash flow. Liquidity is excellent and leverage is modest, providing resilience and flexibility to invest. Continued margin discipline and efficient capital deployment could lift ROE and sustain durable earnings growth.
Why Buy Merit Medical Systems Inc. Stock? MMSI Key Strengths
- Strong revenue growth of 11.8% YoY with net income growth of 6.8%, indicating solid top-line momentum and operational leverage
- Excellent liquidity position with 4.34x current ratio and $446.4M cash providing substantial financial flexibility
- Robust free cash flow generation of $215.7M (14.2% FCF margin) with low capital intensity, enabling debt reduction or reinvestment
- Conservative leverage at 0.46x debt/equity with fortress-like 23.0x interest coverage ratio
- Healthy gross margin of 48.7% indicating strong pricing power and manufacturing efficiency in medical devices
- Consistent double-digit revenue growth with 48.7% gross margin
- Robust free cash flow and 14.2% FCF margin
- Excellent liquidity and conservative leverage with 23x interest coverage
MMSI Stock Risks: Merit Medical Systems Inc. Investment Risks
- Modest operating margin of 12.2% and net margin of 8.5% suggest operational challenges or competitive pressures in core markets
- Low ROE (8.1%) and ROA (4.8%) indicate capital is not generating optimal returns relative to asset base
- Significant long-term debt of $734.0M against equity of $1.6B requires sustained cash flow to manage debt service
- Medical device sector faces regulatory risks, reimbursement pressures, and product obsolescence challenges
- EPS growth (4.9%) lagging revenue growth (11.8%) suggests dilution or margin compression despite topline strength
- Margin pressure from mix, operating costs, or pricing could constrain EPS growth
- Regulatory/reimbursement and product recall risks inherent to medical devices
- Working capital or capital allocation missteps could weaken cash conversion and ROE
Key Metrics to Watch
- Operating margin trajectory - need to see expansion above 12.2% to justify valuation
- Free cash flow sustainability - monitor if FCF conversion rate of 14.2% of revenue can be maintained
- Debt reduction progress - track debt/equity ratio trend and absolute debt levels against cash generation
- Revenue growth consistency - confirm if 11.8% growth is sustainable or cyclical in medical devices market
- Return on equity improvement - ROE of 8.1% needs to expand toward double digits
- Operating margin and FCF conversion
- Net leverage and ROE trajectory
Merit Medical Systems Inc. (MMSI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.34x current ratio provides a solid financial cushion.
MMSI Profit Margin, ROE & Profitability Analysis
MMSI vs Healthcare Sector: How Merit Medical Systems Inc. Compares
How Merit Medical Systems Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Merit Medical Systems Inc. Stock Overvalued? MMSI Valuation Analysis 2026
Based on fundamental analysis, Merit Medical Systems Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Merit Medical Systems Inc. Balance Sheet: MMSI Debt, Cash & Liquidity
MMSI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Merit Medical Systems Inc.'s revenue has grown significantly by 41% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.62 reflects profitable operations.
MMSI Revenue Growth, EPS Growth & YoY Performance
MMSI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $339.8M | $27.8M | $0.46 |
| Q2 2025 | $338.0M | $28.2M | $0.54 |
| Q1 2025 | $323.5M | $28.2M | $0.48 |
| Q3 2024 | $315.2M | $20.2M | $0.44 |
| Q2 2024 | $320.1M | $20.2M | $0.35 |
| Q1 2024 | $297.6M | $20.7M | $0.36 |
| Q3 2023 | $287.2M | $10.5M | $0.27 |
| Q2 2023 | $295.0M | $10.5M | $0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Merit Medical Systems Inc. Dividends, Buybacks & Capital Allocation
MMSI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Merit Medical Systems Inc. (CIK: 0000856982)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MMSI
What is the AI rating for MMSI?
Merit Medical Systems Inc. (MMSI) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MMSI's key strengths?
Claude: Strong revenue growth of 11.8% YoY with net income growth of 6.8%, indicating solid top-line momentum and operational leverage. Excellent liquidity position with 4.34x current ratio and $446.4M cash providing substantial financial flexibility. ChatGPT: Consistent double-digit revenue growth with 48.7% gross margin. Robust free cash flow and 14.2% FCF margin.
What are the risks of investing in MMSI?
Claude: Modest operating margin of 12.2% and net margin of 8.5% suggest operational challenges or competitive pressures in core markets. Low ROE (8.1%) and ROA (4.8%) indicate capital is not generating optimal returns relative to asset base. ChatGPT: Margin pressure from mix, operating costs, or pricing could constrain EPS growth. Regulatory/reimbursement and product recall risks inherent to medical devices.
What is MMSI's revenue and growth?
Merit Medical Systems Inc. reported revenue of $1.5B.
Does MMSI pay dividends?
Merit Medical Systems Inc. does not currently pay dividends.
Where can I find MMSI SEC filings?
Official SEC filings for Merit Medical Systems Inc. (CIK: 0000856982) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MMSI's EPS?
Merit Medical Systems Inc. has a diluted EPS of $2.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MMSI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Merit Medical Systems Inc. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MMSI stock overvalued or undervalued?
Valuation metrics for MMSI: ROE of 8.1% (sector avg: 15%), net margin of 8.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MMSI stock in 2026?
Our dual AI analysis gives Merit Medical Systems Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MMSI's free cash flow?
Merit Medical Systems Inc.'s operating cash flow is $297.4M, with capital expenditures of $81.7M. FCF margin is 14.2%.
How does MMSI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.5% (avg: 12%), ROE 8.1% (avg: 15%), current ratio 4.34 (avg: 2).